TALOTTA, ROSSELLA
 Distribuzione geografica
Continente #
NA - Nord America 412
AS - Asia 47
EU - Europa 31
AF - Africa 4
OC - Oceania 2
Totale 496
Nazione #
US - Stati Uniti d'America 412
CN - Cina 22
IT - Italia 18
VN - Vietnam 17
IN - India 8
FI - Finlandia 7
SC - Seychelles 4
DE - Germania 3
AU - Australia 1
GB - Regno Unito 1
IE - Irlanda 1
NL - Olanda 1
NZ - Nuova Zelanda 1
Totale 496
Città #
Chandler 74
Fairfield 68
Woodbridge 56
Ashburn 35
Seattle 31
Cambridge 27
Houston 23
Ann Arbor 18
Dong Ket 17
Wilmington 17
Des Moines 9
Medford 7
Princeton 7
Cagliari 6
Beijing 5
Helsinki 4
Padova 4
Hebei 3
Jinan 3
Pune 3
Boardman 2
Jiaxing 2
New York 2
Rome 2
Acton 1
Aprilia 1
Auckland 1
Canberra 1
Changsha 1
Chengdu 1
Crotone 1
Cypress 1
Downers Grove 1
Dublin 1
Groningen 1
Hefei 1
Lanzhou 1
Legnano 1
Los Angeles 1
Milan 1
Nanjing 1
Ningbo 1
Norwalk 1
San Diego 1
San Mateo 1
Shenyang 1
Vicenza 1
Wuhan 1
Zhengzhou 1
Totale 450
Nome #
Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: Cause for concern? 104
The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses 95
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: A case series 95
Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response 81
Algo-dysfunctional syndromes: A critical digest of the recent literature 53
Immunogenicity during the treatment of chronic rheumatic diseases: focus on TH9 lymphocytes 52
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 27
Totale 507
Categoria #
all - tutte 1.811
article - articoli 1.550
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.361


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201927 0 0 0 0 0 0 0 0 0 0 14 13
2019/202091 7 3 0 4 9 3 11 15 11 12 11 5
2020/202183 7 7 1 1 8 5 1 5 15 0 14 19
2021/2022101 6 15 8 8 0 2 5 9 1 7 11 29
2022/2023108 16 15 10 17 9 16 1 10 10 1 3 0
2023/202445 1 5 2 6 1 15 3 11 0 1 0 0
Totale 507